Literature DB >> 22677435

MicroRNA 16 enhances differentiation of human bone marrow mesenchymal stem cells in a cardiac niche toward myogenic phenotypes in vitro.

Ju-Li Liu1, Li Jiang, Qiu-Xiong Lin, Chun-Yu Deng, Li-Ping Mai, Jie-Ning Zhu, Xiao-Hong Li, Xi-Yong Yu, Shu-Guang Lin, Zhi-Xin Shan.   

Abstract

AIM: Upregulation of microRNA 16 (miR-16) contributed to the differentiation of human bone marrow mesenchymal stem cells (hMSCs) toward myogenic phenotypes in a cardiac niche, the present study aimed to determine the role of miR-16 in this process. MAIN
METHODS: hMSCs and neonatal rat ventricular myocytes were co-cultured indirectly in two chambers to set up a cardiac microenvironment (niche). miRNA expression profile in cardiac-niche-induced hMSCs was detected by miRNA microarray. Cardiac marker expression and cell cycle analysis were determined in different treatment hMSCs. Quantitative real-time PCR and Western blot were used to identify the expression of mRNA, mature miRNA and protein of interest. KEY
FINDINGS: miRNA dysregulation was shown in hMSCs after cardiac niche induction. miR-16 was upregulated in cardiac-niche-induced hMSCs. Overexpression of miR-16 significantly increased G1-phase arrest of the cell cycle in hMSCs and enhanced the expression of cardiac marker genes, including GATA4, NK2-5, MEF2C and TNNI3. Differentiation-inducing factor 3 (DIF-3), a G0/G1 cell cycle arrest compound, was used to induce G1 phase arrest in cardiac-niche-induced hMSCs, and the expression of cardiac marker genes was up-regulated in DIF-3-treated hMSCs. The expression of CCND1, CCND2 and CDK6 was suppressed by miR-16 in hMSCs. CDK6, CCND1 or CCND2 knockdown resulted in G1 phase arrest in hMSCs and upregulation of cardiac marker gene expression in hMSCs in a cardiac niche. SIGNIFICANCE: miR-16 enhances G1 phase arrest in hMSCs, contributing to the differentiation of hMSCs toward myogenic phenotypes when in a cardiac niche. This mechanism provides a novel strategy for pre-modification of hMSCs before hMSC-based transplantation therapy for severe heart diseases. Crown
Copyright © 2012. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22677435     DOI: 10.1016/j.lfs.2012.05.011

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  12 in total

1.  The caspase-8 shRNA-modified mesenchymal stem cells improve the function of infarcted heart.

Authors:  Yeyou Liang; Qiuxiong Lin; Jiening Zhu; Xiaohong Li; Yongheng Fu; Xiao Zou; Xiaoying Liu; Honghong Tan; Chunyu Deng; Xiyong Yu; Zhixin Shan; Weiwei Yuan
Journal:  Mol Cell Biochem       Date:  2014-07-25       Impact factor: 3.396

2.  The expression of NPPA splice variants during mouse cardiac development.

Authors:  Masoumeh Fakhr Taha; Arash Javeri
Journal:  DNA Cell Biol       Date:  2015-01       Impact factor: 3.311

Review 3.  Epigenetic mechanisms underlying cardiac degeneration and regeneration.

Authors:  Pankaj Chaturvedi; Suresh C Tyagi
Journal:  Int J Cardiol       Date:  2014-02-20       Impact factor: 4.164

4.  miR-16-5p Is a Novel Mediator of Venous Smooth Muscle Phenotypic Switching.

Authors:  Dengshen Zhang; Jun Shi; Guiyou Liang; Daxing Liu; Jian Zhang; Sisi Pan; Yuanfu Lu; Qin Wu; Changyang Gong; Yingqiang Guo
Journal:  J Cardiovasc Transl Res       Date:  2022-05-02       Impact factor: 4.132

5.  c-Myc Represses Tumor-Suppressive microRNAs, let-7a, miR-16 and miR-29b, and Induces Cyclin D2-Mediated Cell Proliferation in Ewing's Sarcoma Cell Line.

Authors:  Masanori Kawano; Kazuhiro Tanaka; Ichiro Itonaga; Tatsuya Iwasaki; Hiroshi Tsumura
Journal:  PLoS One       Date:  2015-09-22       Impact factor: 3.240

6.  Attenuation of microRNA-16 derepresses the cyclins D1, D2 and E1 to provoke cardiomyocyte hypertrophy.

Authors:  Shuai Huang; Xiao Zou; Jie-Ning Zhu; Yong-Heng Fu; Qiu-Xiong Lin; Ye-You Liang; Chun-Yu Deng; Su-Juan Kuang; Meng-Zhen Zhang; Yu-Lin Liao; Xi-Long Zheng; Xi-Yong Yu; Zhi-Xin Shan
Journal:  J Cell Mol Med       Date:  2015-01-13       Impact factor: 5.310

Review 7.  Mesenchymal stem cells in cardiac regeneration: a detailed progress report of the last 6 years (2010-2015).

Authors:  Aastha Singh; Abhishek Singh; Dwaipayan Sen
Journal:  Stem Cell Res Ther       Date:  2016-06-04       Impact factor: 6.832

8.  HEART DISEASE. Titin mutations in iPS cells define sarcomere insufficiency as a cause of dilated cardiomyopathy.

Authors:  John T Hinson; Anant Chopra; Navid Nafissi; William J Polacheck; Craig C Benson; Sandra Swist; Joshua Gorham; Luhan Yang; Sebastian Schafer; Calvin C Sheng; Alireza Haghighi; Jason Homsy; Norbert Hubner; George Church; Stuart A Cook; Wolfgang A Linke; Christopher S Chen; J G Seidman; Christine E Seidman
Journal:  Science       Date:  2015-08-28       Impact factor: 47.728

9.  Inhibition of microRNA‑16 protects mesenchymal stem cells against apoptosis.

Authors:  Jiang Rui; Shaohong Fang; Yongchen Wang; Bo Lv; Bo Yu; Shufeng Li
Journal:  Mol Med Rep       Date:  2018-05-11       Impact factor: 2.952

10.  Lentivirus‑mediated microRNA‑26a overexpression in bone mesenchymal stem cells facilitates bone regeneration in bone defects of calvaria in mice.

Authors:  Zhi Liu; Hong Chang; Yihong Hou; Yu Wang; Zhiqiang Zhou; Ming Wang; Zhidong Huang; Bin Yu
Journal:  Mol Med Rep       Date:  2018-10-25       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.